96 results
424B3
COEP
Coeptis Therapeutics Holdings Inc
26 Mar 24
Prospectus supplement
6:30am
product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and foreign … shares previously issued which are reacquired in satisfaction of tax withholding obligations or as consideration for the exercise or purchase price
424B3
COEP
Coeptis Therapeutics Holdings Inc
26 Mar 24
Prospectus supplement
6:30am
to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and foreign regulatory authorities, despite having progressed through pre-clinical … reacquired will revert to and again become available for issuance under the Plan. Any shares previously issued which are reacquired in satisfaction
424B3
COEP
Coeptis Therapeutics Holdings Inc
30 Nov 23
Prospectus supplement
5:00pm
to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and foreign regulatory authorities, despite having progressed through pre … available for issuance under the Plan. Any shares previously issued which are reacquired in satisfaction of tax withholding obligations or as consideration
8-K
EX-10.4
89m5yhazjk9
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
EX-4.4
om3vk99a157finxq3w5
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
EX-99.1
br2 pslflp
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
EX-4.3
031frig vqn1hp09abtq
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
EX-10.1
to9p0m0nxek 1wr
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
EX-4.2
tqc4pbdwa 19pr18
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
EX-10.5
zhx8g936wi zt
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
EX-4.1
cis3rww5 pgk
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
EX-10.3
l0mq5 e75hu7
22 Aug 23
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
4:01pm
8-K
EX-4.4
2leh4i35y
16 Jun 23
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million
5:15pm
8-K
EX-1.1
51p 9b5gsuvw7z9mlbx2
16 Jun 23
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million
5:15pm